A modern twice-yearly injectable regimen for HIV treatment has demonstrated high rates of viral suppression and a favorable safety profile in a Phase 2 clinical trial, offering a potential shift in how the virus is managed. The regimen, combining the drugs lenacapavir, teropavimab, and zinlirvimab, could represent the first complete long-acting HIV treatment requiring dosing only twice a year, significantly reducing the burden of daily medication for people living with HIV.
The findings, published in The Lancet Microbe, mark a significant milestone in HIV research. Currently, many individuals manage the virus with daily oral antiretroviral therapy (ART). This new approach aims to provide comparable viral suppression with a dramatically reduced dosing schedule, potentially improving adherence and quality of life for patients. The study enrolled adults already on treatment and with virologically suppressed virus who were eligible to switch from their daily oral ART.
Study Details and Findings
The Phase 2 randomized, open-label study was conducted across 34 clinical sites in the U.S., Canada, Australia, and Puerto Rico, including the UNC Clinical Trials Unit in Chapel Hill, North Carolina. Participants either switched to the twice-yearly injectable regimen or continued their daily oral ART. Researchers, led by Joe Eron, MD, of the UNC Institute for Global Health and Infectious Diseases, found that the injectable regimen achieved high rates of viral suppression at 26 weeks.
Dr. Eron, the Herman and Louise Smith Distinguished Professor of Medicine and Chief of UNC’s Infectious Diseases, explained that whereas individual components of the regimen – lenacapavir and broadly neutralizing antibodies – have been studied previously, this is the first time a complete combination suitable for maintenance therapy with twice-yearly dosing has been evaluated in a Phase 2 trial. According to Joseph Eron’s profile on ResearchGate, his areas of interest include antiretroviral therapy, resistance, and HIV persistence.
How the Regimen Works
The injectable regimen utilizes a combination of three drugs. Lenacapavir is a capsid inhibitor, while teropavimab and zinlirvimab are broadly neutralizing antibodies (bNAbs). BNAbs function by targeting and neutralizing the virus, preventing it from infecting new cells. The combination approach aims to provide robust and durable viral suppression with less frequent administration. The study focused on participants whose virus was highly susceptible to the two bNAbs, teropavimab and zinlirvimab.
Implications for HIV Treatment
This research builds on previous advancements in long-acting HIV treatment. In February 2026, a trial demonstrated the efficacy and safety of a twice-yearly injectable HIV regimen, as reported by UNC Global Health. The current study represents a further step toward simplifying HIV management and improving patient outcomes. The potential benefits of less frequent dosing include increased convenience, reduced pill burden, and potentially improved adherence to treatment, which are all crucial factors in maintaining viral suppression and preventing drug resistance.
MedicalXpress reported on the study, highlighting its significance as a potential turning point in HIV treatment. Read more on MedicalXpress.
What’s Next?
While these Phase 2 results are promising, further research is needed to confirm the long-term efficacy and safety of the twice-yearly injectable regimen. Larger Phase 3 trials will be essential to evaluate the regimen in a broader population and to assess its durability over extended periods. If successful, this approach could significantly transform the landscape of HIV treatment, offering a more convenient and effective option for people living with the virus.
Have you or someone you know been impacted by HIV? Share your thoughts and experiences in the comments below. Please also share this article with your network to raise awareness about the latest advancements in HIV treatment.
Disclaimer: This article provides informational content about medical research and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any questions you may have regarding a medical condition.
